Human Papillomavirus Worldwide Distribution in Women Without Cervical Cancer

Dutra, Inês; Foroni, I.; Couto, Ana Rita; Lima, Manuela; Bruges-Armas, Jácome

doi:10.5772/27116

Cited by 2 publications

(4 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In South America, Brazil has the highest incidence of cervical cancer, with a prevalence of HPV infection among women with normal cervical cytology of 21.1%, being the northern and northeastern regions with higher mortality than eastern and southern states (Dutra et al , 2012). In another study developed in Rio Grande do Sul state, the prevalence of HPV-DNA found in women with normal cytology was of 32.7% (Coser et al , 2013).…”

Section: Discussionmentioning

confidence: 99%

“…In the present study, the prevalence of HPV-DNA was 12.7% and was similar to that found in a meta-analysis study, in which the estimated global HPV prevalence in women with normal cytology was 11.7% ( Bruni et al , 2010 ). In South America, Brazil has the highest incidence of cervical cancer, with a prevalence of HPV infection among women with normal cervical cytology of 21.1%, being the northern and northeastern regions with higher mortality than eastern and southern states ( Dutra et al , 2012 ). In another study developed in Rio Grande do Sul state, the prevalence of HPV-DNA found in women with normal cytology was of 32.7% ( Coser et al , 2013 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Association between human papillomavirus (HPV) DNA and micronuclei in normal cervical cytology

et al. 2014

View full text Add to dashboard Cite

The aim of the present study was to investigate the association between HPV-DNA and micronucleus (MN) frequency in women with normal cervical cytology. A total of 158 normal cervical smears were analyzed cytologically. The HPV genome was amplified using the GP5+/bioGP6+ consensus primers. HPV-DNA of high-risk types 16, 18, 31, 33, 39, 45 and 59 were also investigated. Of the 158 samples, 20 (12.7%) and 47 (29.7%) were positive for HPV-DNA and MN, respectively. Evidence for MN was found in 11 out of 20 (55%) HPV-DNA positive samples and in 36 out of 138 (26.1%) HPV-DNA negative ones. MN presence was significantly higher in HPV-DNA positive samples (p = 0.016). On the other hand, the absence of MN observed in a considerable number of HPV-DNA negative samples (102) may be of great value in predicting the absence of HPV. The mean age of HPV-DNA positive women (34.2 ± 12.6) was significantly lower than the mean age of HPV-DNA negative women (43.9 ± 13.7) (p = 0.003). Infection by one or multiple HPV types was found in 11 out of 20 (55.0%) and 9 out of 20 (45.0%) samples, respectively. The evaluation of MN using cervical smears collected for cytology tests could, thus, be used as additional information to monitor a population’s exposure to HPV.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Association between human papillomavirus (HPV) DNA and micronuclei in normal cervical cytology

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Further within the vaccine era among sexually active females aged between 14 to 24 years, the combined prevalence of above subtypes was lower in vaccinated (> 1 dose)compared with unvaccinated females 2.1% vs 16.9% 14 . The most prevalent subtypes of HPV infection was different from geographical region to region 15 . Further, there are various studies even from the same geographical area reported the different distribution of HPV subtypes from time to time 3,[15][16][17][18][19] .…”

Section: Human Papillomavirus (Hpv) Vaccinesmentioning

confidence: 96%

“…The most prevalent subtypes of HPV infection was different from geographical region to region 15 . Further, there are various studies even from the same geographical area reported the different distribution of HPV subtypes from time to time 3,[15][16][17][18][19] . These findings have obvious implications on the decision of implementing HPV vaccination as a preventive strategy for cervical cancer and also to pick the appropriate vaccine for the programme.…”

Section: Human Papillomavirus (Hpv) Vaccinesmentioning

confidence: 96%

“Human Papilloma Virus Vaccination for cervical cancer prevention. Is it safe and effective?”

Gunawardane¹

2018

Bangladesh J Med Sci

View full text Add to dashboard Cite

Human papillomavirus (HPV) causes cervical cancer, which is the fourth most common cancer in women. Most of the cervical cancers are linked to genital infection with HPV and it is the most common viral infection of the reproductive tract. At present, there are three types of HPV vaccines available. Even though HPV vaccination is a primary prevention tool, that does not eliminate the need for routine cervical screening, since the vaccines do not protect against all high-risk HPV types. Ninety percent of HPV infections have no clinical consequences at all whether they are high-risk or low-risk subtypes of HPV. All three types of HPV vaccines have very high vaccine efficacy for prevention of HPV infection among females aged 14 to 26 years. Proper assessment of the safety of HPV vaccine is a problem even after proper systematic review since the most of the clinical trials on the safety of the vaccines were used Hepatitis A vaccine or high immunogenicity enhancing aluminium adjuvant as their placebo. HPV vaccination would be very cost effective for the countries when there is no cervical screening program or if the programme coverage is very poor.Bangladesh Journal of Medical Science Vol.17(3) 2018 p.329-336

show abstract

Human Papillomavirus Worldwide Distribution in Women Without Cervical Cancer

Cited by 2 publications

References 81 publications

Association between human papillomavirus (HPV) DNA and micronuclei in normal cervical cytology

Association between human papillomavirus (HPV) DNA and micronuclei in normal cervical cytology

“Human Papilloma Virus Vaccination for cervical cancer prevention. Is it safe and effective?”

Contact Info

Product

Resources

About